Virus-like structures for combination antigen protein mRNA vaccination DOI Creative Commons
Jingjing Zhang, Yanmei Li,

Fengyuan Zeng

et al.

Nature Nanotechnology, Journal Year: 2024, Volume and Issue: 19(8), P. 1224 - 1233

Published: May 27, 2024

Abstract Improved vaccination requires better delivery of antigens and activation the natural immune response. Here we report a lipid nanoparticle system with capacity to carry antigens, including mRNA proteins, which is formed into virus-like structure by surface decoration spike demonstrating application against SARS-CoV-2 variants. The strategy uses S1 protein from Omicron BA.1 on deliver XBB.1. particle enables specific augmentation mRNAs expressed in human respiratory epithelial cells macrophages via interaction ACE2 or DC-SIGN receptors. Activation dendritic demonstrated same receptor binding. combination increases antibody response BALB/c mice compared vaccines alone. Our exploration mechanism this robust immunity suggests it might involve cross-presentation diverse subsets ranging activated innate signals adaptive signals.

Language: Английский

A Comprehensive review on Pharmacokinetic Studies of Vaccines: Impact of delivery route, carrier-and its modulation on immune response DOI
Saurav Kumar Jha, Mohammad Imran, Laxmi Akhileshwar Jha

et al.

Environmental Research, Journal Year: 2023, Volume and Issue: 236, P. 116823 - 116823

Published: Aug. 3, 2023

Language: Английский

Citations

20
Importance, Applications and Features of Assays Measuring SARS-CoV-2 Neutralizing Antibodies DOI Open Access
Pia Gattinger, Anna Ohradanova‐Repic, Rudolf Valenta

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(6), P. 5352 - 5352

Published: March 10, 2023

More than three years ago, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) caused unforeseen COVID-19 pandemic with millions of deaths. In meantime, SARS-CoV-2 has become endemic and is now part repertoire viruses causing seasonal severe respiratory infections. Due to several factors, among them development immunity through natural infection, vaccination current dominance seemingly less pathogenic strains belonging omicron lineage, situation stabilized. However, challenges remain possible new occurrence highly variants remains a threat. Here we review development, features importance assays measuring neutralizing antibodies (NAbs). particular focus on in vitro infection molecular interaction studying binding receptor domain (RBD) its cognate cellular ACE2. These assays, but not measurement SARS-CoV-2-specific per se, can inform us whether produced by convalescent or vaccinated subjects may protect against thus have potential predict risk becoming newly infected. This information extremely important given fact that considerable number subjects, vulnerable persons, respond poorly production antibodies. Furthermore, these allow determine evaluate virus-neutralizing capacity induced vaccines administration plasma-, immunoglobulin preparations, monoclonal antibodies, ACE2 synthetic compounds be used for therapy assist preclinical evaluation vaccines. Both types relatively quickly adapted emerging virus about magnitude cross-neutralization, which even estimate infected appearing variants. Given paramount discuss their specific features, advantages disadvantages, technical aspects yet fully resolved issues, such as cut-off levels predicting degree vivo protection.

Language: Английский

Citations

19
Nasal vaccination of triple-RBD scaffold protein with flagellin elicits long-term protection against SARS-CoV-2 variants including JN.1 DOI Creative Commons

Xian Li,

Mengxin Xu, Jingyi Yang

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: April 27, 2024

Abstract Developing a mucosal vaccine against SARS-CoV-2 is critical for combatting the epidemic. Here, we investigated long-term immune responses and protection intranasal vaccination of triple receptor-binding domain (RBD) scaffold protein (3R-NC) adjuvanted with flagellin (KFD) ( 3R-NC + KFDi.n ). In mice, elicited RBD-specific broad-neutralizing antibody in both serum sites sustained at high level over year. This long-lasting humoral immunity was correlated presence long-lived IgG- IgA-producing plasma cells, alongside Th17 Tfh17-biased T-cell driven by KFD adjuvant. Based upon these preclinical findings, an open labeled clinical trial conducted individuals who had been primed inactivated (IAV) vaccine. With favorable safety profile, boost enduring IgG IgA salivary secretions. To meet challenge frequently emerged variants, further designed updated triple-RBD mutated RBD combinations, which can induce adaptable to neutralize newly emerging including JN.1. Our findings highlight potential KFD-adjuvanted promising prototype development infection.

Language: Английский

Citations

7
Vaccines for the Elderly and Vaccination Programs in Europe and the United States DOI Creative Commons
Cleo Anastassopoulou, Stefanos Ferous, Snežana Medić

et al.

Vaccines, Journal Year: 2024, Volume and Issue: 12(6), P. 566 - 566

Published: May 22, 2024

The share of the elderly population is growing worldwide as life expectancy increases. Immunosenescence and comorbidities increase infectious diseases’ morbidity mortality in older adults. Here, we aimed to summarize latest findings on vaccines for against herpes zoster, influenza, respiratory syncytial virus (RSV), COVID-19, pneumococcal disease examine vaccine recommendation differences this age group Europe United States. PubMed was searched using keywords “elders” “vaccine” alongside disease/pathogen question paraphrased or synonymous terms. Vaccine recommendations were also sought European US Centers Disease Control Prevention databases. Improved vaccines, tailored elderly, mainly by novel adjuvants increasing antigen concentration, are now available. Significant exist between immunization policies, especially countries, terms recipient’s age, number doses, vaccination schedule, implementation (mandatory recommended). Understanding factors that influence immune response may help design offer long-term protection vulnerable group. A consensus-based strategy could fill gaps policy particularly regarding RSV pneumococcus.

Language: Английский

Citations

7
Virus-like structures for combination antigen protein mRNA vaccination DOI Creative Commons
Jingjing Zhang, Yanmei Li,

Fengyuan Zeng

et al.

Nature Nanotechnology, Journal Year: 2024, Volume and Issue: 19(8), P. 1224 - 1233

Published: May 27, 2024

Abstract Improved vaccination requires better delivery of antigens and activation the natural immune response. Here we report a lipid nanoparticle system with capacity to carry antigens, including mRNA proteins, which is formed into virus-like structure by surface decoration spike demonstrating application against SARS-CoV-2 variants. The strategy uses S1 protein from Omicron BA.1 on deliver XBB.1. particle enables specific augmentation mRNAs expressed in human respiratory epithelial cells macrophages via interaction ACE2 or DC-SIGN receptors. Activation dendritic demonstrated same receptor binding. combination increases antibody response BALB/c mice compared vaccines alone. Our exploration mechanism this robust immunity suggests it might involve cross-presentation diverse subsets ranging activated innate signals adaptive signals.

Language: Английский

Citations

7